The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates

References

• Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253–4
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: Review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527–34
   PubMed Web of Science ®Google Scholar
• Sanna G, Zampino MG, Pelosi G, Nolè F, Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of biphosphonates. Ann Oncol 2005; 16: 1207–8
   PubMed Web of Science ®Google Scholar
• Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99–102
   PubMed Web of Science ®Google Scholar
• Marx RE. Pamidronate (Aredia) and Zolendronate (Zometa) induced avascular bone necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–8
   PubMed Web of Science ®Google Scholar
• Dannemann C, Gratz KW, Riener MO, Zwalhen RA. Jaw osteonecrosis related to bisphosphonate therapy. A severe secondary disorder. Bone 2007; 40: 828–34
   PubMed Web of Science ®Google Scholar
• Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: A report of twenty-nine cases. Acta Biomed 2006; 77: 109–17
   PubMedGoogle Scholar
• Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006; 17: 1512–6
   PubMed Web of Science ®Google Scholar
• Donoghue M. Bisphosphonates and osteonecrosis: Analogy to phoss jaw. Med J Aust 2005; 183: 163–4
   PubMed Web of Science ®Google Scholar
• Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 2005; 63: 682–9
   PubMed Web of Science ®Google Scholar
• Ardine M., Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?. Ann Oncol 2006; 17: 1336–7
   PubMed Web of Science ®Google Scholar
• Green JR. Bisphosphonates: Preclinical review. Oncologist 2004; 9(Suppl 4)3–13
   PubMed Web of Science ®Google Scholar
• Grau AJ, Becher H, Ziegler CM, Lichy C, Buggle F, Kaiser C, et al. Periodontal disease as a risk factor for ischemic stroke. Stroke 2004; 35: 496–501
   PubMed Web of Science ®Google Scholar
• Parfitt AM. Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994; 55: 2273
   Google Scholar
• Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055–61
   PubMed Web of Science ®Google Scholar
• Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538–44
   PubMed Web of Science ®Google Scholar
• Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006; 24: 945–52
   PubMed Web of Science ®Google Scholar
• Nastro E, Musolino C, Allegra A, Oteri G, Cicciu M, Alonci A, et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 2007; 117: 181–7
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433–41
   PubMed Web of Science ®Google Scholar
• Diego R, D'Orto O, Pagani D, Agazzi A, Marzano U, Derada Troletti G, et al. Bisphosphonate-associated osteonecrosis of the jaws -- a therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 1–5
   PubMedGoogle Scholar
• Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 2007;99:1016–24. Epub 2007.
   PubMed Web of Science ®Google Scholar